Learn more: PMC Disclaimer | PMC Copyright Notice
Correction for: ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
2
and Ning Li
3
This article has been corrected: The authors found an error in Figure 3B. During assembly of the figure, incorrect images of colonies formed by ACC cell lines in which ASXL1 was silenced by shRNA#1 (KD1) were used. The authors prepared a new Figure 3 using representative images from the original experiments. This correction has no impact on the main conclusion. The authors would like to apologize for any inconvenience caused.
New Figure 3 is presented below.
Silencing of ASXL1 decreased fitness of adrenocortical carcinoma (ACC) cells. (A) Cell count detected using CCK-8 in ACC cell lines with ASXL1-knockdown (KD) by shRNA#1 and shRNA#2 (KD1 and KD2) or negative control (NC); (B) Colony formation in ACC cell lines with ASXL1 silencing or control; Flow cytometry used to detect (C) cell cycle profile and (D) apoptosis in ACC cells with ASXL1-KD or NC; (E) Transwell assays used to detect cell invasion with Matrigel in ACC cells with ASXL1-KD or NC, captured at 100×; (F) Wound healing assay in ACC cells with ASXL1-KD or NC (**P < 0.01).